Department of Biological Chemistry, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA.
Division of Hematology/Oncology, Department of Medicine, University of California Irvine, 839 Medical Sciences Rd, Sprague Hall 126, Irvine, CA, 92617, USA.
Curr Hematol Malig Rep. 2019 Jun;14(3):145-153. doi: 10.1007/s11899-019-00508-w.
Chronic inflammation is a characteristic feature of myeloproliferative neoplasm (MPN) and impacts many aspects of the disease including initiation, progression, and symptomatology.
The chronic inflammatory state of MPN results from disruption of immune signaling pathways leading to overproduction of inflammatory cytokines by both the neoplastic clones and bystander immune cells. This chronic inflammation may allow for the neoplastic clone to gain a selective advantage. The symptomatic burden felt by MPN patients may be a result of the chronic inflammation associated with MPN, as several cytokines have been linked with different symptoms. Pharmacologic as well as nonpharmacologic treatments of the inflammatory component of this disease may lead to decreased symptomatic burden, prevention of disease progression, and improvement in overall disease trajectory. Inflammation plays a key role in the pathogenesis of MPN and represents an important therapeutic target.
慢性炎症是骨髓增殖性肿瘤(MPN)的特征之一,影响疾病的许多方面,包括发病、进展和症状学。
MPN 的慢性炎症状态源于免疫信号通路的破坏,导致肿瘤克隆和旁观者免疫细胞过度产生炎性细胞因子。这种慢性炎症可能使肿瘤克隆获得选择性优势。MPN 患者的症状负担可能是与 MPN 相关的慢性炎症的结果,因为几种细胞因子与不同的症状有关。这种疾病炎症成分的药物和非药物治疗可能会减轻症状负担,预防疾病进展,并改善整体疾病轨迹。炎症在 MPN 的发病机制中起关键作用,是一个重要的治疗靶点。